Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$1.25 ▼ -0.05
(-3.85%)
MKT CAP: $431.9M • VOL: 7.71M
52W L $1 52W H $4
ROARABLE / RQD
D- • 38/100
PIOTROSKI
3 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$1
MEDIAN
$1
MEAN
$1
HIGH
$2
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ALLO TAPE
ALLO // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $1.51 | $1.44 | 2025-02-14 | $1.14 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $1.57 | $1.47 | 2025-02-06 | $1.17 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $1.42 | $1.38 | 2025-01-29 | $1.20 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $1.27 | — | 2025-01-17 | $1.23 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $1.10 | $1.19 | 2025-01-09 | $1.11 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $1.49 | $1.30 | 2024-12-18 | $1.09 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $1.21 | $1.26 | 2024-12-04 | $1.16 | -4.3% | 48% | C |